Compare LAKE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | ADCT |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 136.1M |
| IPO Year | 2013 | 2019 |
| Metric | LAKE | ADCT |
|---|---|---|
| Price | $10.13 | $1.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $15.25 | $3.33 |
| AVG Volume (30 Days) | 51.8K | ★ 1.3M |
| Earning Date | 09-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,648,000.00 | $81,357,000.00 |
| Revenue This Year | $3.47 | N/A |
| Revenue Next Year | $8.33 | $26.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.21 | 14.85 |
| 52 Week Low | $7.15 | $0.78 |
| 52 Week High | $18.00 | $4.98 |
| Indicator | LAKE | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 49.99 |
| Support Level | $9.58 | $0.99 |
| Resistance Level | $11.38 | $1.20 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 2.04 | 56.45 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe, and Other Foreign. It generates the majority of its revenue from the United States.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).